Published in Lancet on March 01, 2011
Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ (2014) 5.84
Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. BMJ (2012) 5.26
Benzodiazepine use and risk of dementia: prospective population based study. BMJ (2012) 4.32
The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol (2014) 2.99
Multimorbidity patterns in primary care: interactions among chronic diseases using factor analysis. PLoS One (2012) 1.71
Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp Neurol (2011) 1.49
Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42
Increased Risk of Dementia in Patients With Erectile Dysfunction: A Population-Based, Propensity Score-Matched, Longitudinal Follow-Up Study. Medicine (Baltimore) (2015) 1.39
MicroRNAs and neurodegeneration: role and impact. Trends Cell Biol (2012) 1.38
The adverse effects of air pollution on the nervous system. J Toxicol (2012) 1.28
Neuroinflammation and neurodegeneration in overnutrition-induced diseases. Trends Endocrinol Metab (2012) 1.23
Comorbidity of dementia: a cross-sectional study of primary care older patients. BMC Psychiatry (2014) 1.20
'The clocks that time us'--circadian rhythms in neurodegenerative disorders. Nat Rev Neurol (2014) 1.20
Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS): a misdiagnosed disease entity. J Neurol Sci (2011) 1.18
Periodontitis: a potential risk factor for Alzheimer's disease. Br Dent J (2015) 1.15
Emerging Roles for Long Non-Coding RNAs in Cancer and Neurological Disorders. Front Genet (2012) 1.13
Characterization and molecular profiling of PSEN1 familial Alzheimer's disease iPSC-derived neural progenitors. PLoS One (2014) 1.13
AlzPathway: a comprehensive map of signaling pathways of Alzheimer's disease. BMC Syst Biol (2012) 1.13
Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J Clin Invest (2013) 1.12
At the extreme end of the psychoneuroimmunological spectrum: delirium as a maladaptive sickness behaviour response. Brain Behav Immun (2012) 1.11
Cause or Effect: Misregulation of microRNA Pathways in Neurodegeneration. Front Neurosci (2012) 1.09
Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration. Proc Natl Acad Sci U S A (2013) 1.09
The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond. Front Physiol (2012) 1.09
Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era. Appl Clin Genet (2012) 1.07
Comparison of nine tractography algorithms for detecting abnormal structural brain networks in Alzheimer's disease. Front Aging Neurosci (2015) 1.05
Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailty. Front Aging Neurosci (2014) 1.04
Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol (2011) 1.04
Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol (2012) 1.03
Brain imaging and cognitive predictors of stroke and Alzheimer disease in the Framingham Heart Study. Stroke (2013) 1.02
Alzheimer's disease and risk of hip fracture: a meta-analysis study. ScientificWorldJournal (2012) 1.01
Caregiver burden and psychoeducational interventions in Alzheimer's disease: a review. Dement Geriatr Cogn Dis Extra (2012) 1.01
Perspectives on episodic-like and episodic memory. Front Behav Neurosci (2013) 1.00
Impact of aging brain circuits on cognition. Eur J Neurosci (2013) 1.00
Cardiovascular risk factors and future risk of Alzheimer's disease. BMC Med (2014) 1.00
Reduction in inflammation and the expression of amyloid precursor protein and other proteins related to Alzheimer's disease following gastric bypass surgery. J Clin Endocrinol Metab (2012) 0.99
The association of APOE genotype with cognitive function in persons aged 35 years or older. PLoS One (2011) 0.98
Canonical Wnt signaling protects hippocampal neurons from Aβ oligomers: role of non-canonical Wnt-5a/Ca(2+) in mitochondrial dynamics. Front Cell Neurosci (2013) 0.98
Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant? Biochem J (2012) 0.97
Connecting the dots between tau dysfunction and neurodegeneration. Trends Cell Biol (2014) 0.97
The potential role of dopamine D₃ receptor neurotransmission in cognition. Eur Neuropsychopharmacol (2013) 0.97
Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One (2012) 0.97
Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem (2012) 0.96
Brain regional correlation of amyloid-β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-β accumulation. Acta Neuropathol (2013) 0.96
Relationship between markers of insulin resistance, markers of adiposity, HbA1c, and cognitive functions in a middle-aged population-based sample: the MONA LISA study. Diabetes Care (2012) 0.95
Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med (2012) 0.95
All-d-Enantiomer of β-Amyloid Peptide Forms Ion Channels in Lipid Bilayers. J Chem Theory Comput (2012) 0.95
Alzheimer's disease: a clinical practice-oriented review. Front Neurol (2012) 0.95
The protective and therapeutic function of small heat shock proteins in neurological diseases. Front Immunol (2012) 0.94
Amyloid β (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J Biol Chem (2012) 0.94
Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med (2015) 0.93
Tau aggregation and its interplay with amyloid-β. Acta Neuropathol (2014) 0.93
SIRT1 in the brain-connections with aging-associated disorders and lifespan. Front Cell Neurosci (2015) 0.93
'Kitchen and cooking,' a serious game for mild cognitive impairment and Alzheimer's disease: a pilot study. Front Aging Neurosci (2015) 0.93
Natural compounds may open new routes to treatment of amyloid diseases. Neurotherapeutics (2013) 0.92
Deep brain stimulation and cognitive decline in Parkinson's disease: a clinical review. Front Neurol (2012) 0.92
Antioxidant gene therapy against neuronal cell death. Pharmacol Ther (2013) 0.92
Genetic determinants of disease progression in Alzheimer's disease. J Alzheimers Dis (2015) 0.92
Polygenic Analysis of Late-Onset Alzheimer's Disease from Mainland China. PLoS One (2015) 0.92
Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease. J Inorg Biochem (2011) 0.91
Carbon nanotubes and graphene as emerging candidates in neuroregeneration and neurodrug delivery. Int J Nanomedicine (2015) 0.91
LKB1 and AMP-activated protein kinase: regulators of cell polarity. Genes Cells (2012) 0.91
Astrocytes conspire with neurons during progression of neurological disease. Curr Opin Neurobiol (2012) 0.90
Brain microvasculature and hypoxia-related proteins in Alzheimer's disease. Int J Clin Exp Pathol (2011) 0.90
Genetics of Alzheimer's disease. Biomed Res Int (2013) 0.90
Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One (2012) 0.90
Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Curr Alzheimer Res (2015) 0.90
A cross-sectional study on thyroid status in North Indian elderly outpatients with dementia. Ann Indian Acad Neurol (2013) 0.90
Translatability scoring in drug development: eight case studies. J Transl Med (2012) 0.89
Amyloid-β peptide binds to cytochrome C oxidase subunit 1. PLoS One (2012) 0.89
SUMO and Alzheimer's disease. Neuromolecular Med (2013) 0.89
Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. Biochem Pharmacol (2014) 0.89
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther (2014) 0.89
Salubrinal attenuates β-amyloid-induced neuronal death and microglial activation by inhibition of the NF-κB pathway. Neurobiol Aging (2011) 0.89
Postsynaptic Receptors for Amyloid-β Oligomers as Mediators of Neuronal Damage in Alzheimer's Disease. Front Physiol (2012) 0.89
Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease. Alzheimers Res Ther (2013) 0.89
The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease. Curr Alzheimer Res (2016) 0.89
Advances in the prevention of Alzheimer's Disease. F1000Prime Rep (2015) 0.89
Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. Mediators Inflamm (2015) 0.89
Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. Pharmaceuticals (Basel) (2013) 0.88
Mobile technologies in the early detection of cognitive decline. PLoS One (2014) 0.88
Induced pluripotent stem cells to model and treat neurogenetic disorders. Neural Plast (2012) 0.88
Molecular basis of inhibitory activities of berberine against pathogenic enzymes in Alzheimer's disease. ScientificWorldJournal (2012) 0.88
Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia. Front Aging Neurosci (2013) 0.88
Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. Trials (2011) 0.88
GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain (2015) 0.88
Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon. J Biol Chem (2012) 0.88
Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nat Rev Drug Discov (2011) 0.87
Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus. J Diabetes Investig (2015) 0.87
Age-related changes in core body temperature and activity in triple-transgenic Alzheimer's disease (3xTgAD) mice. Dis Model Mech (2012) 0.87
Alzheimer's disease: relevant molecular and physiopathological events affecting amyloid-β brain balance and the putative role of PPARs. Front Aging Neurosci (2014) 0.86
ATP5H/KCTD2 locus is associated with Alzheimer's disease risk. Mol Psychiatry (2013) 0.86
Caregiver Burden in Alzheimer's Disease: Differential Associations in Adult-Child and Spousal Caregivers in the GERAS Observational Study. Dement Geriatr Cogn Dis Extra (2014) 0.86
Clinico-pathological correlations of the most common neurodegenerative dementias. Front Neurol (2012) 0.86
Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. Neurobiol Aging (2015) 0.86
Interactions of AChE with Aβ Aggregates in Alzheimer's Brain: Therapeutic Relevance of IDN 5706. Front Mol Neurosci (2011) 0.86
Precortical Phase of Alzheimer's Disease (AD)-Related Tau Cytoskeletal Pathology. Brain Pathol (2015) 0.86
Clinical Features of Alzheimer Disease With and Without Lewy Bodies. JAMA Neurol (2015) 0.85
Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. CNS Neurol Disord Drug Targets (2012) 0.85
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Global prevalence of dementia: a Delphi consensus study. Lancet (2005) 23.30
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol (2006) 6.97
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Age, neuropathology, and dementia. N Engl J Med (2009) 6.36
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
UK health performance: findings of the Global Burden of Disease Study 2010. Lancet (2013) 6.11
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet (2002) 5.05
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ (2011) 4.37
The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol (2009) 4.17
Epidemiology of Alzheimer disease. Nat Rev Neurol (2011) 4.13
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature (2012) 4.08
Prevalence of autism-spectrum conditions: UK school-based population study. Br J Psychiatry (2009) 3.97
Political drive to screen for pre-dementia: not evidence based and ignores the harms of diagnosis. BMJ (2013) 3.93
Vascular cognitive impairment. Lancet Neurol (2003) 3.73
Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature (2010) 3.58
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke (2006) 3.27
Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up. BMJ (2008) 3.03
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord (2006) 2.96
Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc (2011) 2.88
A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord (2008) 2.81
Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet (2007) 2.73
Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol (2010) 2.72
A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord (2005) 2.70
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain (2012) 2.64
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord (2006) 2.47
Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology (2007) 2.32
Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord (2014) 2.30
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain (2010) 2.29
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
Analysis of longitudinal studies with death and drop-out: a case study. Stat Med (2004) 2.24
Inability to get up after falling, subsequent time on floor, and summoning help: prospective cohort study in people over 90. BMJ (2008) 2.23
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry (2004) 2.21
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry (2013) 2.20
The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry (2011) 2.08
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord (2006) 2.04
Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord (2012) 1.99
The burden of diseases on disability-free life expectancy in later life. J Gerontol A Biol Sci Med Sci (2007) 1.98
Attrition and bias in the MRC cognitive function and ageing study: an epidemiological investigation. BMC Public Health (2004) 1.97
What sleep characteristics predict cognitive decline in the elderly? Sleep Med (2012) 1.96
Carotid sinus hypersensitivity in asymptomatic older persons: implications for diagnosis of syncope and falls. Arch Intern Med (2006) 1.94
Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry (2009) 1.91
Trachoma survey methods: a literature review. Bull World Health Organ (2009) 1.90
Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol (2002) 1.88
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet (2012) 1.88
The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study. PLoS Med (2005) 1.86
Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol (2009) 1.86
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol (2012) 1.86
Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc (2003) 1.83
A global model for effective use and evaluation of e-learning in health. Telemed J E Health (2013) 1.82
Educational differences in the dynamics of disability incidence, recovery and mortality: Findings from the MRC Cognitive Function and Ageing Study (MRC CFAS). Int J Epidemiol (2007) 1.82
Multiple biological pathways link cognitive lifestyle to protection from dementia. Biol Psychiatry (2011) 1.79
Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc (2008) 1.74
T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res (2012) 1.74
DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet (2006) 1.73
Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med (2009) 1.72
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol (2010) 1.70
What do we mean by Alzheimer's disease? BMJ (2010) 1.69
Education, the brain and dementia: neuroprotection or compensation? Brain (2010) 1.68
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.66
Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods (2008) 1.62
Improvement of episodic memory in persons with mild cognitive impairment and healthy older adults: evidence from a cognitive intervention program. Dement Geriatr Cogn Disord (2006) 1.57
Training-related brain plasticity in subjects at risk of developing Alzheimer's disease. Brain (2011) 1.56
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord (2007) 1.55
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry (2010) 1.55
Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord (2009) 1.54
Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry (2009) 1.54
Prevalence and causes of blindness and low vision in southern Sudan. PLoS Med (2006) 1.54
Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology (2005) 1.53
Associations between active trachoma and community intervention with Antibiotics, Facial cleanliness, and Environmental improvement (A,F,E). PLoS Negl Trop Dis (2008) 1.52
Does depression predict adverse outcomes for older medical inpatients? A prospective cohort study of individuals screened for a trial. Age Ageing (2008) 1.52
Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J Immunol (2003) 1.52
Neuropsychological profile of patients with Parkinson's disease without dementia. Dement Geriatr Cogn Disord (2003) 1.51
Diseases and impairments as risk factors for onset of disability in the older population in England and Wales: findings from the Medical Research Council Cognitive Function and Ageing Study. J Gerontol A Biol Sci Med Sci (2005) 1.50
CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2010) 1.50
Measuring strategic control in artificial grammar learning. Conscious Cogn (2011) 1.50
Risk factors for incident dementia in England and Wales: The Medical Research Council Cognitive Function and Ageing Study. A population-based nested case-control study. Age Ageing (2006) 1.49